TF
Therapeutic Areas
HilleVax Pipeline
| Drug | Indication | Phase |
|---|---|---|
| HIL-214 | Prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection | Phase 2b/3 |
| Drug | Indication | Phase |
|---|---|---|
| HIL-214 | Prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection | Phase 2b/3 |